Last updated: August 6, 2026
Primidone is an established, low-cost antiseizure medicine with an expired originator estate and substantial generic competition. The strongest commercial opportunities are not basic tablet replication. They are differentiated oral dosage forms, pediatric and geriatric products, taste-masked liquids, rapid-dispersing tablets, supply-resilient formulations, and products designed for markets with limited generic availability.
What is the commercial profile of primidone?
Primidone is an oral anticonvulsant approved in the United States under the Mysoline brand. It is used primarily for generalized and focal seizures and is also used for essential tremor. Primidone is metabolized in part to phenobarbital and phenylethylmalonamide, which contribute to its pharmacologic activity. The drug is administered chronically, creating recurring demand for reliable, low-cost oral products.
| Attribute |
Primidone |
| Active ingredient |
Primidone |
| Molecular formula |
C12H14N2O2 |
| Molecular weight |
218.25 g/mol |
| Main dosage forms |
Tablets; oral suspension opportunities |
| Common strengths |
50 mg, 125 mg, 250 mg |
| Main indications |
Epilepsy; essential tremor |
| Originator |
Mysoline |
| U.S. regulatory pathway |
NDA-originated product with generic ANDA competition |
| Biosimilar relevance |
None; primidone is a synthetic small molecule |
| Commercial category |
Mature, low-cost generic |
| Key formulation issues |
Dose flexibility, swallowing, content uniformity, taste, dissolution, supply cost |
FDA labeling identifies 50 mg, 125 mg and 250 mg tablet presentations for Mysoline. Generic products may not carry every strength or dosage form, creating opportunities for manufacturers that can improve availability or patient usability.[1,2]
What excipients are used in primidone tablets?
Commercial primidone tablets commonly use conventional direct-compression or wet-granulation excipients. Exact composition varies by manufacturer and should be confirmed against the applicable DailyMed label, approved product record and CMC documentation.
Typical excipient classes include:
| Formulation function |
Candidate excipient classes |
Commercial purpose |
| Diluent |
Lactose, microcrystalline cellulose, dibasic calcium phosphate, mannitol |
Provides tablet mass and improves compression |
| Binder |
Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose |
Improves granule and tablet strength |
| Disintegrant |
Crospovidone, croscarmellose sodium, sodium starch glycolate |
Controls tablet breakup and dissolution |
| Lubricant |
Magnesium stearate, sodium stearyl fumarate |
Reduces die-wall friction |
| Glidant |
Colloidal silicon dioxide, talc |
Improves powder flow |
| Film coating |
Hypromellose, polyethylene glycol, titanium dioxide, iron oxides |
Improves handling, identification and swallowability |
| Suspension vehicle |
Purified water, cellulose derivatives, suspending polymers, wetting agents |
Enables liquid administration |
| Sweetener and flavor |
Sucralose, saccharin sodium, sorbitol, sucrose, fruit flavors |
Improves pediatric acceptability |
Excipient selection should preserve dose uniformity across low-strength tablets. A 50 mg product has a higher risk of content-uniformity failure than a 250 mg product when the active is poorly distributed through the blend. Geometric dilution, controlled particle-size distribution and validated blending are more important than selecting a novel excipient.
Which excipients are most suitable for a standard generic tablet?
A practical first-line formulation uses microcrystalline cellulose or lactose as the primary diluent, a low concentration of povidone or pregelatinized starch as binder, crospovidone or croscarmellose sodium as disintegrant, colloidal silicon dioxide as glidant and magnesium stearate as lubricant.
For a cost-sensitive product, lactose-based or starch-containing systems can reduce formulation cost. For a lactose-free product, microcrystalline cellulose, mannitol or dibasic calcium phosphate can replace lactose. Dibasic calcium phosphate may improve tablet hardness but can change compression behavior and dissolution.
Magnesium stearate concentration and mixing time require tight control. Over-lubrication can reduce tablet tensile strength and slow dissolution. Sodium stearyl fumarate is a potential alternative where lubricant sensitivity or dissolution performance requires it.
What formulation challenges affect primidone product development?
How should developers manage solubility and dissolution?
Primidone has limited aqueous solubility relative to highly soluble immediate-release drugs. The formulation target should be rapid and reproducible dissolution rather than simply high tablet hardness. Particle-size reduction, wetting agents, porous carriers and optimized disintegrants can improve dissolution without adding unnecessary complexity.
Potential approaches include:
- Micronized primidone with controlled particle-size distribution.
- Crospovidone or croscarmellose sodium to promote rapid breakup.
- Low levels of sodium lauryl sulfate or poloxamer where justified by compatibility and safety data.
- Spray-dried or co-processed excipient systems to improve content uniformity.
- Amorphous solid dispersion only if dissolution testing demonstrates a material benefit.
A conventional immediate-release formulation is usually preferable to an amorphous dispersion for a mature generic drug. Solid-state instability, moisture sensitivity and manufacturing cost can outweigh the benefit of higher apparent solubility.
How should developers address dose flexibility?
Dose flexibility is commercially important because seizure treatment is titrated and patients may require different maintenance doses. A 50 mg tablet is useful for initiation and titration, while 125 mg and 250 mg tablets support maintenance dosing.
Scored tablets can improve dose adjustment, but the score must meet applicable subdivision and uniformity requirements. A scored 250 mg tablet may reduce pill burden but can create breakage and dose-variation risks if the tablet is too hard, too friable or poorly scored.
A portfolio containing 50 mg, 125 mg and 250 mg tablets can support pharmacy substitution and reduce the need for multiple tablets. The commercial value is higher where competitors omit the 125 mg strength.
Is an oral liquid formulation commercially attractive?
An oral liquid is the clearest dosage-form opportunity. It can address patients who cannot swallow tablets, children requiring titration and patients receiving enteral nutrition. The product must manage primidone's limited aqueous solubility, palatability and physical stability.
A suspension is generally more practical than a simple aqueous solution when solubility is insufficient. The product should be designed for:
- Uniform dose delivery after shaking.
- Controlled sedimentation and easy redispersion.
- Low viscosity sufficient for oral syringes.
- Preservative effectiveness where a multidose container is used.
- Compatibility with plastic bottles and oral dosing devices.
- Acceptable taste after repeated administration.
Candidate suspending systems include xanthan gum, microcrystalline cellulose and carboxymethylcellulose combinations, or other pharmaceutically accepted polymer systems. The final choice should be based on sedimentation volume, redispersibility, viscosity, syringeability and stability.
Taste masking is a major development issue. Sweeteners alone may not adequately cover the drug's taste. Flavor systems, polymeric taste barriers, ion-exchange resins or coated drug particles can be evaluated. Ion-exchange approaches may be difficult because they can affect dose release and create additional control requirements.
The pediatric opportunity requires more than a liquid dosage form. FDA expects age-appropriate dosing, measuring-device accuracy, excipient justification and palatability assessment under applicable pediatric development standards.[3]
What are the strongest commercial opportunities for primidone?
Which primidone dosage forms have the best commercial potential?
| Opportunity |
Patient or buyer need |
Development complexity |
Commercial assessment |
| 50 mg scored tablet |
Titration and dose adjustment |
Low |
Strongest near-term generic opportunity |
| 125 mg tablet |
Intermediate maintenance dose |
Low |
Attractive where supply is limited |
| 250 mg tablet |
Maintenance therapy and lower pill burden |
Low |
Competitive but operationally efficient |
| Oral suspension |
Pediatrics, dysphagia, enteral use |
Moderate to high |
Highest differentiation potential |
| Orally disintegrating tablet |
Swallowing difficulty and portability |
Moderate |
Potential niche product |
| Taste-masked granules |
Pediatric and caregiver use |
High |
Potentially differentiated |
| Unit-dose packaging |
Adherence and institutional use |
Low to moderate |
Useful in hospitals and long-term care |
| Combination product |
Simplified seizure regimen |
High |
Limited near-term opportunity because of clinical and regulatory burden |
An orally disintegrating tablet could address patients with dysphagia, but it would face taste-masking and dose-loading constraints, particularly at 250 mg. A 50 mg or 125 mg ODT is more technically plausible than a high-strength ODT.
Can a primidone product obtain 505(b)(2) protection?
A conventional primidone tablet normally fits the ANDA pathway because the reference product is well established and the active ingredient is approved. A materially different dosage form, such as a novel oral suspension, modified-release product or complex taste-masked system, may support a 505(b)(2) application if the sponsor relies in part on FDA findings for an approved product while presenting new clinical, pharmacokinetic or formulation data.
The pathway does not automatically create meaningful market exclusivity. Any exclusivity or patent position would depend on the product's specific innovation, labeling, clinical data and patent claims. A reformulated product also carries a higher development burden than an ANDA.
What patents protect primidone products?
The core primidone compound and the original Mysoline tablet technology are old and are not expected to provide current U.S. exclusivity. Primidone is a mature small-molecule product, and generic competition has existed for many years.
What is the Orange Book status of primidone?
FDA's Orange Book is the controlling source for listed patents, exclusivity and reference-product information. Public FDA product records identify primidone as an established NDA product with generic alternatives. The standard primidone tablet market is generally an ANDA market rather than an active originator-patent market.[4]
A sponsor evaluating a new product should distinguish among:
- Expired compound patents.
- Expired formulation patents.
- Current patents, if any, listed for a specific approved product.
- Unlisted formulation know-how.
- Trade secrets covering manufacturing, taste masking or process control.
- Patent rights in non-U.S. jurisdictions.
A new liquid, ODT, multiparticulate or controlled-release product could generate patentable claims around composition, particle engineering, release behavior, manufacturing process and dosing method. Those claims would protect only the disclosed innovation, not ordinary primidone tablets generally.
Are Paragraph IV challenges relevant to primidone?
Paragraph IV litigation is unlikely to be a central barrier for ordinary primidone tablets because the principal product estate is mature. A Paragraph IV certification would become relevant if a new branded or 505(b)(2) primidone product obtained listed patents covering a specific formulation, delivery system or method of use.
For an ANDA sponsor, the principal risks are more likely to involve bioequivalence, manufacturing observations, product-quality compliance, supply continuity and market crowding than a live compound patent.
Does primidone have biosimilar risk?
No. Primidone is a chemically synthesized small molecule, not a biologic. It is subject to generic-drug competition through the ANDA framework, not biosimilar competition under the Public Health Service Act.
The competitive risk is therefore conventional generic erosion, pharmacy substitution, contract pricing and product discontinuation. A differentiated formulation may reduce direct price competition but will not eliminate substitution pressure.
How strong is the primidone patent estate?
The patent estate for standard primidone tablets is weak from an exclusivity perspective because the active ingredient and long-standing tablet presentations are mature. The commercial defensibility of a new product would come from execution and differentiated claims rather than legacy patents.
| Estate component |
Strength for standard tablets |
Implication |
| Compound protection |
Very low |
No meaningful exclusivity |
| Original tablet formulation |
Very low |
Broad generic access |
| New suspension composition |
Potentially moderate |
Requires specific technical claims |
| Taste-masking technology |
Moderate if technically narrow |
Design-around risk must be assessed |
| ODT formulation |
Moderate |
Protection depends on composition and performance |
| Manufacturing process |
Moderate to high if difficult to reproduce |
Trade-secret and process-patent value |
| Method of use |
Low to moderate |
Clinical evidence and claim scope are decisive |
Manufacturing barriers can still create practical defensibility. These include narrow particle-size specifications, segregation control at low dose, difficult suspension redispersion, preservative compatibility and stability failures in high-humidity markets.
What FDA regulatory issues affect primidone excipient strategy?
The FDA expects each excipient to be justified for route, dose, population and exposure. A formulation using established excipients within known oral-use levels has a lower regulatory burden than one using novel excipients or unusual exposure levels.
Key regulatory workstreams include:
- Comparative dissolution against the reference product.
- Assay and content uniformity across strengths.
- Tablet subdivision testing for scored tablets.
- Stability under ICH long-term and accelerated conditions.
- Extractables and leachables for liquid packaging.
- Preservative effectiveness for multidose suspensions.
- Shake-time and redispersibility studies.
- Dosing-device accuracy.
- Compatibility with enteral feeding tubes if that use is claimed.
- Nitrosamine and elemental-impurity risk assessments where applicable.
- Excipient specification and supplier-change controls.
For an ANDA, bioequivalence remains the central requirement. For a suspension or novel dosage form, the sponsor may need additional in vitro and pharmacokinetic evidence. Any food-effect, formulation-dependent absorption or metabolite-exposure concern should be addressed during development.
Which companies are challenging the primidone market?
The primidone market is served primarily by generic manufacturers and distributors rather than by a single dominant innovator. Product availability can vary by strength, country and wholesaler. The competitive landscape is driven by:
- FDA-approved ANDA holders.
- Contract manufacturers.
- Regional generic companies.
- Hospital and institutional suppliers.
- Private-label distributors.
- International manufacturers supplying markets outside the United States.
The main commercial opening is a reliable product in an under-supplied strength or dosage form. A sponsor should avoid assuming that a mature molecule has no opportunity. Generic discontinuations, limited manufacturer participation and pharmacy shortages can create temporary pricing windows, although those windows can close quickly when additional suppliers enter.
What generic launch scenarios exist for primidone?
Scenario 1: Low-cost standard tablet
This is the fastest route and has the lowest technical risk. It requires competitive manufacturing cost, adequate supply and all commercially relevant strengths. Margins are likely to be limited.
Scenario 2: Complete strength portfolio
A manufacturer offering 50 mg, 125 mg and 250 mg tablets can compete for pharmacy and institutional contracts more effectively than a supplier with one strength. The 125 mg product may provide the best portfolio differentiation.
Scenario 3: Pediatric and dysphagia-focused suspension
A stable, palatable suspension can command a higher price and reduce direct tablet-only competition. The product requires more extensive formulation development, packaging work and regulatory support.
Scenario 4: Specialty pharmacy and long-term-care product
Unit-dose packaging, oral syringes and clear administration instructions can target long-term-care facilities and medication-management programs. The opportunity depends on procurement contracts rather than patent exclusivity.
Scenario 5: International market entry
Countries with limited primidone supply may offer opportunities for local registration and licensing. Geographic coverage requires separate review of national patent status, reference-product requirements, excipient permissions, labeling rules and pharmacovigilance obligations.
What licensing opportunities exist for primidone?
Licensing value is more likely to attach to a differentiated formulation or manufacturing platform than to primidone itself. Potential deal structures include:
- Regional rights for an oral suspension.
- Co-development of a pediatric dosage form.
- Contract manufacturing and supply agreements.
- In-licensing of taste-masking technology.
- Private-label supply for institutional buyers.
- Out-licensing of a novel delivery system.
- Technology transfer for low-dose blending or multiparticulate manufacturing.
A licensing package should define territory, dosage forms, regulatory ownership, minimum purchase obligations, quality agreements, shortage allocation and rights to improvements. Because the base molecule is inexpensive, transaction economics depend heavily on forecast volume, manufacturing yield and reimbursement.
Key Takeaways
- Primidone is a mature generic small molecule with little practical exclusivity for standard tablets.
- The strongest commercial opportunity is a differentiated oral suspension serving pediatric, geriatric and dysphagia populations.
- A complete 50 mg, 125 mg and 250 mg strength portfolio can improve pharmacy and institutional competitiveness.
- Excipient strategy should prioritize content uniformity, rapid dissolution, tablet robustness, taste masking and suspension redispersibility.
- Standard tablets are best suited to an ANDA strategy; novel liquids and delivery systems may support 505(b)(2) development.
- Biosimilar risk does not apply. The principal risks are generic price competition, supply concentration and regulatory execution.
- Patent value is more likely to arise from new formulation, process, packaging or delivery claims than from legacy primidone rights.
- Licensing opportunities center on differentiated dosage forms, manufacturing technology and regional supply rights.
FAQs
Can lactose be used in primidone tablets?
Yes. Lactose is a conventional oral-tablet diluent and may be suitable if compatibility, patient labeling and product-performance requirements are met. Lactose-free alternatives include microcrystalline cellulose, mannitol and dibasic calcium phosphate.
What is the best excipient for a primidone suspension?
No single excipient is universally optimal. A cellulose-based or xanthan-based suspending system should be screened against sedimentation, redispersibility, viscosity, syringeability, taste and stability targets.
Is primidone a good candidate for an orally disintegrating tablet?
It may be suitable at lower strengths, particularly 50 mg or 125 mg, but taste masking and dose loading are substantial development issues. A 250 mg ODT is technically more difficult.
Can a primidone suspension be sold as a generic?
Potentially. The regulatory pathway depends on the reference product, dosage-form differences and FDA requirements for bioequivalence and product characterization. A materially different product may require a 505(b)(2) application rather than a conventional ANDA.
Does primidone have pediatric formulation demand?
Yes. Pediatric patients may require liquid administration, flexible titration and accurate low-volume dosing. A palatable, stable suspension with a validated oral syringe is the most direct formulation response.
References
-
U.S. Food and Drug Administration. (2024). Mysoline (primidone) prescribing information. FDA/DailyMed.
-
National Library of Medicine. (2024). DailyMed: Primidone tablet product labeling. U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (2020). Quality considerations for chewable tablets: Guidance for industry. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.
